Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
110
Trial Sponsor
Clinical Trial Start Date
January 8, 2018
0Primary Completion Date
June 13, 2020
0Study Completion Date
June 13, 2020
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Intervention Name
MVA-BN-Brachyury/ FPV-Brachyury0
Interventional Trial Phase
Phase 10
Official Name
An Open-label Phase 1 Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-BN-Brachyury/FPV-Brachyury)0
Last Updated
August 26, 2020
0Allocation Type
NA0
Intervention Model
Sequential Assignment0
Masking Type
None (Open Label)0
Study summary
An open-label Phase 1 trial to evaluate the safety and tolerability of MVA-BN-Brachyury priming and FPV-Brachyury boost vaccines modified to express brachyury and T-cell costimulatory molecules in patients with a metastatic or unresectable locally advanced malignant solid tumor. Subjects will be given the following subcutaneous doses: two prime doses with MVA-BN-Brachyury and monthly boost doses with FPV-Brachyury for 6 months. The study will last approximately 104 weeks before starting long term follow up (FU).
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
